Exelixis (EXEL) Morgan Stanley 23rd Annual Global Healthcare Conference summary

Company overview and strategic focus

• Focused on oncology with a lead product, CABOMETYX (cabozantinib), approved in multiple indications and driving strong revenue growth, including a recent launch in neuroendocrine tumors (NETs).

• Emphasizes differentiation and innovation, aiming to replicate CABO's success across a growing pipeline.

• Engages with Chinese biotech innovation, leveraging assets originated in China and closely monitoring opportunities for collaboration and global expansion.

• Utilizes AI to improve efficiency and performance, especially in R&D, while maintaining a cautious approach to investment in new technologies.

• Maintains disciplined capital allocation, balancing R&D investment, internal pipeline growth, and shareholder returns through buybacks.

Regulatory and market environment

• Regulatory complexity is increasing, with government chargebacks like 340B significantly impacting financial flows between manufacturers and hospitals.

• Emphasizes the need for careful consideration of regulatory changes to avoid unintended long-term consequences for innovation and patient care.

CABOMETYX (cabozantinib) performance and outlook

• CABO recently launched in NETs, capturing 4% of business in its first full quarter, equating to about $20 million in revenue.

• The NET oral therapy market is estimated at $1 billion annually, with CABO aiming to increase market share over the next few years.

• Long-term sales guidance targets nearly $3 billion by the end of the decade, requiring a 10–11% CAGR, with NETs and base business as key drivers.

• Commercial success is seen as fueling further pipeline development and franchise expansion.